Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Description

Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.

Conditions

Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis

Talk to us

Study Overview

On this page

Study Details

Study overview

Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Condition
Cryoglobulinemic Vasculitis (CV)
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

Boston

Boston University School of Medicine, Boston, Massachusetts, United States, 02118

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Cleveland

Cleveland Clinic, Cleveland, Ohio, United States, 44195

Portland

Oregon Health & Science University, Portland, Oregon, United States,

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Salt Lake City

University of Utah, Salt Lake City, Utah, United States,

Charlottesville

University of Virginia, Charlottesville, Virginia, United States, 22903

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have a cutaneous lesion (purpuric macules, palpable purpura, retiform purpura, nodules, ulcers, or urticarial) believed to be related to active vasculitis
  • * Have a suspected or confirmed diagnosis of:
  • * Cryoglobulinemic vasculitis (CV)
  • * Drug-induced vasculitis
  • * Eosinophilic granulomatosis with polyangiitis (EGPA)
  • * IgA vasculitis
  • * Isolated cutaneous vasculitis
  • * Granulomatosis with polyangiitis (GPA)
  • * Microscopic polyangiitis (MPA)
  • * Polyarteritis nodosa (PAN)
  • * Urticarial vasculitis
  • * Be willing and able to provide written informed consent (or assent for those under
  • * You are less than five years old
  • * Considered not to be a candidate for a biopsy or have a higher risk of developing an infection, bleeding, etc., from the biopsy, or a doctor believes that the risks for you participating in this study do not outweigh the potential benefit of learning information from your biopsy
  • * You have a neutrophil count (type of white blood cell) less than 1500/mm3, platelet count less than 50,000/mm3, or a hemoglobin less than 7 g/dL
  • * You have an uncontrolled disease that could prevent you from completing the study procedures
  • * You have an active infection at or near the potential biopsy site, have poor circulation, or have bony prominence or other structure that would increase your risk of complications if you participated in this study
  • * You are pregnant or nursing
  • * You are not able to provide informed consent

Ages Eligible for Study

5 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Peter Merkel,

Robert Micheletti, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Peter Grayson, MD, MSc, PRINCIPAL_INVESTIGATOR, The National Institute of Arthritis and Musculoskeletal and Skin Diseases

Study Record Dates

2024-12